drugset / Trial / NCT03615144
TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the participant's disease.
Timeline
- Start
- 2018-07-23
- Primary completion
- 2020-11-13
- Completion
- 2020-11-13
Outcome
Outcome not reported
Stopped (Enrollment): “Participant accrual low and the study was closed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clofarabine | Other / unclassified | 20 mg/m2 | — |
| Comparator | Clofarabine | Other / unclassified | 30 mg/m2 | — |
| Comparator | Fludarabine | Small molecule | 30 mg/m2 | — |
| Comparator | Melphalan | Small molecule | 70 mg/m2 | — |
| Comparator | Thiotepa | Other / unclassified | 7.5 mg/kg | — |
| Comparator | rabbit anti-thymocyte globulin | Protein / enzyme biologic | 2.5 mg/kg | — |